T
Thomas Becker
Researcher at University of Kiel
Publications - 127
Citations - 5545
Thomas Becker is an academic researcher from University of Kiel. The author has contributed to research in topics: Transplantation & Liver transplantation. The author has an hindex of 39, co-authored 125 publications receiving 4838 citations. Previous affiliations of Thomas Becker include Hannover Medical School & Leibniz University of Hanover.
Papers
More filters
Journal ArticleDOI
Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
Bindhu Madhavan,Shijing Yue,Uwe Galli,Sanyukta Rana,Wolfgang Gross,Miryam Müller,Nathalia A. Giese,Holger Kalthoff,Thomas Becker,Markus W. Büchler,Margot Zöller +10 more
TL;DR: The concomitant evaluation of PaCIC and PaCa‐related miRNA marker panels awaits retrospective analyses of larger cohorts, as it should allow for a highly sensitive, minimally‐invasive PaCa diagnostics.
Journal ArticleDOI
DNA Methylation Analysis in Nonalcoholic Fatty Liver Disease Suggests Distinct Disease-Specific and Remodeling Signatures after Bariatric Surgery
M Ahrens,Ole Ammerpohl,Witigo von Schönfels,Julia Kolarova,Susanne Bens,Timo Itzel,Andreas Teufel,A Herrmann,Mario Brosch,Holger Hinrichsen,Wiebke Erhart,Jan Hendrik Egberts,Bence Sipos,Stefan Schreiber,Robert Häsler,Felix Stickel,Thomas Becker,Michael Krawczak,Christoph Röcken,Reiner Siebert,Clemens Schafmayer,Jochen Hampe +21 more
TL;DR: Liver samples from morbidly obese patients with all stages of NAFLD and controls were analyzed by array-based DNA methylation and mRNA expression profiling, providing an example of treatment-induced epigenetic organ remodeling in humans.
Journal ArticleDOI
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Klemens Budde,Thomas Becker,Wolfgang Arns,Claudia Sommerer,Petra Reinke,Ute Eisenberger,Stefan Kramer,W. Fischer,Harald Gschaidmeier,F Pietruck +9 more
TL;DR: Early elimination of calcineurin inhibitor by use of everolimus-based immunosuppression improved renal function at 12 months while maintaining efficacy and safety, indicating that this strategy may facilitate improved long-term outcomes in selected patients.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
J. O. Medina Pestana,Josep M. Grinyó,Yves Vanrenterghem,Thomas Becker,Josep M. Campistol,Sander Florman,Valter Duro Garcia,Nassim Kamar,Peter Lang,R.C. Manfro,Pablo U. Massari,M Rial,Mark A. Schnitzler,Stefan Vitko,T. Duan,A. Block,M. B. Harler,Antoine Durrbach +17 more
TL;DR: In conclusion, at 3 years after transplantation, immunosuppression with belatacept resulted in similar patient survival, graft survival and acute rejection, with better renal function compared with cyclosporine.